1460772752-71873bab-7cfd-4e48-99cc-276312453349

1. A method of creating mulch comprising the steps:
receiving a quantity of shells;
washing the shells to remove debris therefrom;
at least partially drying the shells;
applying a coloring agent to the shells; and
drying the colored shells.
2. The method as set forth in claim 1, wherein the washing step is performed with an aggregate material washer.
3. The method as set forth in claim 1, wherein the segregating step is performed with two shaker tables.
4. The method as set forth in claim 1, wherein the drying step is performed with one or more conveyors along which are mounted fans andor heating elements.
5. The method as set forth in claim 1, wherein the coloring agent is applied in a screw conveyor.
6. The method as set forth in claim 1, further comprising the step of segregating the shells while washing them to separate relatively larger shells for further processing.
7. A method of creating mulch comprising the steps:
receiving a quantity of shells;
applying a primer mixture to the shells to create primed shells;
drying the primed shells;
applying a coloring agent to the primed shells to created colored shells; and
drying the colored shells.
8. The method as set forth in claim 7, wherein the primer mixture comprises approximately 5-15 cups of dye per ton of shells to be primed.
9. The method as set forth in claim 7, wherein the coloring agent comprises approximately 1-5 gallons of dye and 1-10 gallons of water per ton of shells to be colored.
10. The method as set forth in claim 7, wherein the primer mixture is applied to the shells in a cylinder mixer.
11. The method as set forth in claim 7, wherein the coloring agent is applied to the shells in a cylinder mixer.
12. The method as set forth in claim 7, wherein the primer mixture is applied to the shells by spray nozzles.
13. The method as set forth in claim 7, wherein the coloring agent is applied to the shells by spray nozzles.
14. The method as set forth in claim 7, wherein the drying steps are performed with fans, heaters, andor sunlight.
15. A method of creating mulch from sea shells, the method comprising the steps:
receiving a quantity of sea shells;
washing the sea shells to remove debris therefrom;
placing the washed sea shells into a mixer;
adding a primer mixture to the mixer;
operating the mixer to coat the sea shells with the primer mixture to create primed sea shells;
removing the primed sea shells from the mixer;
drying the primed sea shells;
placing the primed sea shells into a mixer;
adding a coloring agent to the mixer;
operating the mixer to coat the primed sea shells with the coloring agent to create colored sea shells;
drying the colored sea shells; and
packaging the colored sea shells for delivery to customers.
16. The method as set forth in claim 15, wherein the primer mixture comprises approximately 5-15 cups of dye per ton of sea shells to be primed.
17. The method as set forth in claim 15, wherein the coloring agent comprises approximately 1-5 gallons of dye and 1-10 gallons of water per ton of sea shells to be colored.
18. The method as set forth in claim 15, wherein the drying steps are performed with fans, heaters, andor sunlight.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treatment, comprising:
identifying a human patient that is susceptible to ischemia; and
reducing the likelihood of an occurrence of a harmful effect of ischemia by administering an effective amount of a stable free radical prior to the onset of ischemia;
wherein the likelihood is reduced in comparison to a human patient that was not subjected to the administering step.
2. The method of claim 1, wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
3. The method of claim 1, wherein the human patient’s susceptibility to ischemia arises from a medical procedure associated with a significant ischemic risk.
4. The method of claim 3, wherein the medical procedure is the treatment of a hemorrhage.
5. The method of claim 3, wherein the medical procedure is the treatment of an aneurysm.
6. The method of claim 3, wherein the medical procedure is surgery.
7. The method of claim 3, wherein the medical procedure is an endovascular procedure.
8. The method of claim 1, wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
9. A method of treatment comprising:
identifying a patient scheduled to undergo a medical procedure involving a risk of ischemia;
reducing the likelihood of an occurrence of a harmful effect of ischemia by administering to the patient, prior to the medical procedure, an effective amount of a stable free radical nitroxide;
performing the medical procedure; and
administering to the patient, an additional amount of a stable free radical nitroxide to ameliorate a harmful effect of ischemia.
10. The method of claim 9, wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
11. The method of claim 9, wherein the medical procedure is the treatment of a hemorrhage.
12. The method of claim 9, wherein the medical procedure is the treatment of an aneurysm.
13. The method of claim 9, wherein the medical procedure is surgery.
14. The method of claim 9, wherein the medical procedure is an endovascular procedure.
15. The method of claim 9, wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
16. The method of claim 1 wherein the nitroxide is selected from the group consisting of
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH2NH2;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R1 is selected from CH3 and spirocylohexyl, and R2 is selected from C2H5 and spirocyclohexyl;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is CONH;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is H, OH, and NH2;
wherein R1 is \u2014CH3; R2 is \u2014C2H5, \u2014C3H7, \u2014C4H9, \u2014C5H11, \u2014C6H13, \u2014CH2\u2014CH(CH3)2, \u2014CHCH3C2H5, or \u2014(CH2)7\u2014CH3, or wherein R1 and R2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane; R3 is \u2014O. or \u2014OH, or a physiologically acceptable salt thereof which has antioxidant activity;
wherein R3 is \u2014O. or \u2014OH; and
wherein R4 and R5 combine together with the nitrogen to form a heterocyclic group; wherein the atoms in the heterocyclic group (other than the N atom shown in the formula) may be all C atoms or may be C atoms and one or more N, O andor S atoms; or
wherein R4 and R5 combine together to form substituted or unsubstituted pyrrole, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, or purine; or
wherein R4 and R5 themselves comprise a substituted or unsubstituted cyclic or heterocyclic group;
2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl, 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempamine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, 4-oxo-TEMPO, 4-amino-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-(ethoxyfluorophosphonyloxy)-TEMPO, 4-hydroxy-TEMPO, 4-(2-iodo acetamido)-TEMPO, 4-isothiocyanato-TEMPO, 4-maleimido-TEMPO, 4-(4-nitrobenzoyloxyl)-TEMPO, and 4-phosphonooxy-TEMPO.
17. The method of claim 9 wherein the nitroxide is selected from the group consisting of
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R is selected from COOH, CONH, CN, and CH2NH2;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH, and R1 is selected from CH3 and spirocylohexyl, and R2 is selected from C2H5 and spirocyclohexyl;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is CONH;
or a pharmaceutically acceptable salt thereof
wherein X is selected from O. and OH and R is selected from H, OH, and NH2;
wherein R1 is \u2014CH3; R2 is \u2014C2H5, \u2014C3H7, \u2014C4H9, \u2014C5H11, \u2014C6H13, \u2014CH2\u2014CH(CH3)2, \u2014CHCH3C2H5, or \u2014(CH2)7\u2014CH3, or wherein R1 and R2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane; R3 is \u2014O. or \u2014OH, or a physiologically acceptable salt thereof which has antioxidant activity;
wherein R3 is \u2014O. or \u2014OH; and
wherein R4 and R5 combine together with the nitrogen to form a heterocyclic group; wherein the atoms in the heterocyclic group (other than the N atom shown in the formula) may be all C atoms or may be C atoms and one or more N, O andor S atoms; or
wherein R4 and R5 combine together to form substituted or unsubstituted pyrrole, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, or purine; or
wherein R4 and R5 themselves comprise a substituted or unsubstituted cyclic or heterocyclic group;
2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl, 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempamine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, 4-oxo-TEMPO, 4-amino-TEMPO, 4-(2-bromoacetamido)-TEMPO, 4-(ethoxyfluorophosphonyloxy)-TEMPO, 4-hydroxy-TEMPO, 4-(2-iodo acetamido)-TEMPO, 4-isothiocyanato-TEMPO, 4-maleimido-TEMPO, 4-(4-nitrobenzoyloxyl)-TEMPO, and 4-phosphonooxy-TEMPO.
18. A method of treatment comprising:
identifying a human patient who is susceptible to ischemia associated with a medical procedure; and
reducing a harmful effect of ischemia in the human patient after the medical procedure by administering an effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl prior to the onset of ischemia and prior to the medical procedure.
19. The method of claim 18, wherein the human patient’s susceptibility to ischemia arises from a medical procedure associated with a significant ischemic risk.
20. The method of claim 18, wherein the medical procedure is the treatment of a hemorrhage.
21. The method of claim 18, wherein the medical procedure is the treatment of an aneurysm.
22. The method of claim 18, wherein the medical procedure is surgery.
23. The method of claim 18, wherein the medical procedure is an endovascular procedure.
24. The method of claim 18, wherein the mode of nitroxide administration is selected from the group consisting of oral and intravenous administration.
25. A method of treatment comprising:
identifying a patient scheduled to undergo a medical procedure involving a significant risk of ischemia;
reducing a harmful effect of ischemia in the human patient after the medical procedure by administering an effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl performing the medical procedure; and
administering to the patient after the performing step, an additional amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl effective to reduce a harmful effect of ischemia
26. The method of claim 25, wherein the nitroxide is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl.
27. The method of claim 25, wherein the medical procedure is the treatment of a hemorrhage.
28. The method of claim 25, wherein the medical procedure is the treatment of an aneurysm.
29. The method of claim 25, wherein the medical procedure is surgery.
30. The method of claim 25, wherein the medical procedure is an endovascular procedure.